— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being ...
The Dermatology Division of the U.S. Food and Drug Administration has granted Fast Track designation to sonelokimab in moderate-to-severe palmoplantar pustulosis supported by positive results from the ...
The U.S. Food and Drug Administration (FDA) has approved a once-daily GLP-1 pill for weight loss called orforglipron (marketed as Foundayo) for adults with obesity or those who are overweight and have ...
NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today ...
— QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan ...
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results